November 07, 2014
GlaxoSmithKline Pharmaceuticals Limited announced its financial results for the third quarter
ended September 30, 2014.
The core Pharmaceuticals business grew by 20.4% for the quarter. Impact of the previous year
National List of Essential Medicines (NLEM) price adjustments were felt in the corresponding
quarter last year.
Net Profit before exceptional items grew by 31.3% for the quarter.
Dr. Hasit B. Joshipura, Managing Director, said, “The brands impacted by price adjustments
have shown improved volume growth.”
About GlaxoSmithKline:
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the
world’s leading research-based pharmaceutical and healthcare companies, committed to
improving the quality of human life by enabling people to do more, feel better and live longer. For
more information, visit www.gsk-india.com.
For enquiries, please contact:
Nandini Goswami – +91 22 24959203
General Manager, Corporate Communications – nandini.x.goswami@gsk.com
